The longer certain groups of patients with myelodysplastic syndromes (MDS) survive, the lower their likelihood of death or transformation to acute myeloid leukemia (AML), according to a new study of more than 7,000 patients.
The International Working Group for the Prognosis of MDS reported that approximately 3.5 years after diagnosis, MDS patients initially considered to be at high risk for death or AML had outcomes similar to those initially categorized as low-risk patients (Blood